Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Interest Expense : $-10.57 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Cerevel Therapeutics Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cerevel Therapeutics Holdings's interest expense for the three months ended in Dec. 2023 was $ -2.65 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.57 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cerevel Therapeutics Holdings's Operating Income for the three months ended in Dec. 2023 was $ -139.56 Mil. Cerevel Therapeutics Holdings's Interest Expense for the three months ended in Dec. 2023 was $ -2.65 Mil. Cerevel Therapeutics Holdings did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cerevel Therapeutics Holdings Interest Expense Historical Data

The historical data trend for Cerevel Therapeutics Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerevel Therapeutics Holdings Interest Expense Chart

Cerevel Therapeutics Holdings Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-3.92

-10.57

Cerevel Therapeutics Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial												-2.63	-2.64	-2.64	-2.64	-2.65

Cerevel Therapeutics Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.57 Mil.

Cerevel Therapeutics Holdings (NAS:CERE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cerevel Therapeutics Holdings's Interest Expense for the three months ended in Dec. 2023 was $-2.65 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-139.56 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $365.21 Mil.

Cerevel Therapeutics Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Cerevel Therapeutics Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cerevel Therapeutics Holdings (Cerevel Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cerevel Therapeutics Holdings Inc (NAS:CERE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

673:Germany

Address

222 Jacobs Street, Suite 200, Cambridge, MA, USA, 02141

Website

https://www.cerevel.com

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Executives

N Anthony Coles	director, officer: See Remarks	MORRIS CORP. CENTER I; BLDG. B; 4TH FLR., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Ramiro Sanchez	officer: Chief Medical Officer	C/O CEREVELL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kenneth Dipietro	officer: Chief Human Resources Officer	C/O BIOGEN IDEC INC., 133 BOSTON POST ROAD, WESTON MA 02493
Susan Altschuller	officer: Chief Financial Officer	45 TENNYSON ST., SOMERVILLE MA 02145
Mark Bodenrader	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Kathleen Tregoning	officer: See Remarks	C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116
Scott Akamine	officer: Chief Legal Officer	C/O AEON BIOPHARMA, INC., 4040 MACARTHUR BLVD., SUITE 260, NEWPORT BEACH CA 92660
Deval L Patrick	director	BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Perceptive Life Sciences Master Fund Ltd	director	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher R Gordon	director	C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Investors Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Paul D. Burgess	officer: See Remarks	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Renaud Ronald C Jr	director, officer: President & CEO	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Marijn E Dekkers	director	GENERAL ELECTRIC COMPANY, 41 FARNSWORTH STREET, BOSTON MA 02210